UNSPSC 51453010: Piperazine estrone sulfate

This classification denotes an antihelminthic agent with the molecular formula C18H22O5S.C4H10N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SVI38UY019, chemically known as estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, compd. with piperazine (1:1), but more generally known as piperazine estrone sulfate, which bears US NIH Compound Identifier 23703. European Medicines Agency schedules piperazine estrone sulfate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03841MIG.

Most nations, for tariff purposes, schedule piperazine estrone sulfate under HS 29335990. SMILES: C[C@]12CC[C@@H]3C4CCC(CC4CC[C@H]3[C@@H]1CCC2=O)OS(=O)(=O)O.C1CNCCN1.

UNSPSC 51453010 Piperazine estrone sulfate, a Commodity code, shows minimal alignment between its nominal scope and recent state and local procurement activity. The code's technical pharmaceutical designation does not match the products and services state and local governments are actually buying under this coding assignment. Recent solicitations tagged to this code cover naloxone procurement, medical and first aid supplies for emergency response, generic pharmaceuticals through cooperative purchasing, and direct-to-manufacturer prescription programs—none of which concern piperazine estrone sulfate. The Seminole County, Florida IFB for naloxone and drug deactivation systems, the City of Tampa's bid for medical and first aid supplies to the Fire Department Rescue Division, the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic pharmaceuticals and OTC products, and the Texas Health and Human Services Commission RFI for therapeutic pharmacy initiatives all appear to be miscoded to this commodity. State and local buyers using this code are acquiring emergency medical consumables, pharmaceutical supply-chain coordination services, and health agency procurement support—not the specific pharmaceutical ingredient the code nominally describes.

Geographic activity spans Florida, Texas, Minnesota, and Oregon, with the cooperative purchasing structure of MMCAP reaching multiple state jurisdictions simultaneously. Issuing bodies include county health departments (Seminole County), municipal fire services (City of Tampa), state pharmacy benefit administrators (Texas HHS, Minnesota Department of Administration), and multistate cooperative purchasing alliances. The City of Tampa's March 2026 medical and first aid supplies IFB, with a response deadline of March 13, 2026 and an estimated contract value of $700,000, is designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount. The MMCAP RFP for generic pharmaceuticals, due March 26, 2026, establishes contracts across participating state and local facilities effective July 1, 2026. The Seminole County naloxone IFB, posted June 30, 2026, with a due date of July 26, 2023 (an apparent data inconsistency in the source), seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. Given the mismatch between the code's nominal pharmaceutical and the actual procurement activity, this code does not represent a meaningful market opportunity for vendors in the piperazine estrone sulfate supply chain.